open-label study

(redirected from open label trial)

open-label study

a study in which there is no blinding of treatments.
Farlex Partner Medical Dictionary © Farlex 2012

open-label study

A clinical study in which the patients/subjects and investigators know which product each patient/subject is receiving, which is the opposite of a blinded study.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

open-label study

, open label study
A clinical trial without a control group, in which both patients and researchers know the identity of the treatment and its dosage.
See also: study
Medical Dictionary, © 2009 Farlex and Partners
Mentioned in ?
References in periodicals archive ?
The manuscript, entitled 'Stable Intracerebral Transplantation of Neural Stem Cells for the Treatment of Paralysis Due to Ischemic Stroke,' summarizes the results of an open label trial performed at BaYi Brain Hospital in Beijing, China, with Principal Investigator Professor Xu Ruxiang.
M2 PHARMA-June 7, 2019-Concert Pharmaceuticals Completes Enrollment in Open Label Trial to Evaluate Once-Daily vs.
There was great interest at the recent International Headache Congress in Boston in a poster on the results of an open label trial on non-invasive vagus nerve stimulation for the treatment of cluster headache.
Yazici also spoke about the results of ACT-STAR, a prospective, 24-week open label trial, presented at the 2011 ACR meeting by Dr.
The phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicentre, prospective, randomised, open label trial evaluating TB-402 for the prophylaxis of DVT after knee replacement surgery.
"Open label trial of coenzyme Q10 as a migraine preventive." Cephalagia, 2002; 22:137-141.
Her open label trial of glyburide was designed to identify patient characteristics associated with adequate metabolic control using glyburide and to document any maternal or fetal complications associated with the therapy.
This new dose regimen trial is designed to complement the first open label trial initiated by Concert in March 2019, which is ongoing in patients randomized to receive either 8 mg twice-daily or 16 mg once-daily of CTP-543 over a 24 week treatment period.
This open label trial follows the announcement of positive results from an interim analysis of an ongoing placebo-controlled Phase 2 trial that showed significant hair regrowth at 24 weeks with 8 mg twice-daily dosing of CTP-543.
The open label trial is aimed at assessing the safety and efficacy of the product in combination with atezolizumab versus atezolizumab alone in up to 80 patients with locally advanced, relapsed, or metastatic synovial sarcoma or myxoid/round-cell liposarcoma expressing the NY-ESO-1 cancer testis antigen.
This Phase I open label trial is designed to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of TG-1701 in patients with non-Hodgkin's Lymphoma, or NHL and Chronic Lymphocytic Leukemia, or CLL.
The first study was a 223-patient Phase III open label trial in Japan, which indicated the superiority of gadobutrol-enhanced MRI of the central nervous system compared to unenhanced MRI.

Full browser ?